SPONSOR
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Total Trials
5
Recruiting
5
Phases
Phase 2
Conditions studied: Diffuse Large B Cell LymphomaProstate CancerAcute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryStage IV Colorectal CancerCurative ResectionGastric Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Diffuse Large B Cell Lymphoma, Prostate Cancer, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
How many clinical trials has Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, of which 5 are actively recruiting participants. These trials cover conditions including Diffuse Large B Cell Lymphoma, Prostate Cancer, Acute Myeloid Leukemia, in Relapse. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS research focus on?
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS clinical trials span Diffuse Large B Cell Lymphoma, Prostate Cancer, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Stage IV Colorectal Cancer, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS clinical trial?
To participate in a Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS trials with current recruitment status updated daily.
Clinical Trials by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT04300101
Recruiting
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B Cell Lymphoma
NCT05893381 Phase 2
Recruiting
Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Prostate Cancer
NCT06459024
Recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, in Relapse
NCT02919644 Phase 2
Recruiting
Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
Stage IV Colorectal Cancer
NCT04842916
Recruiting
InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer
Gastric Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology